- Home
- BGLC vs SILO Comparison
BGLC vs SILO Comparison
Compare BGLC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- SILO
- Stock Information
- Founded
- BGLC 2017
- SILO 2010
- Country
- BGLC Malaysia
- SILO United States
- Employees
- BGLC N/A
- SILO N/A
- Industry
- BGLC Medical Specialities
- SILO Apparel
- Sector
- BGLC Health Care
- SILO Consumer Discretionary
- Exchange
- BGLC Nasdaq
- SILO Nasdaq
- Market Cap
- BGLC 5.8M
- SILO 4.7M
- IPO Year
- BGLC N/A
- SILO N/A
- Fundamental
- Price
- BGLC $0.38
- SILO $1.96
- Analyst Decision
- BGLC
- SILO
- Analyst Count
- BGLC 0
- SILO 0
- Target Price
- BGLC N/A
- SILO N/A
- AVG Volume (30 Days)
- BGLC 10.9M
- SILO 9.0M
- Earning Date
- BGLC 02-20-2025
- SILO 02-14-2025
- Dividend Yield
- BGLC N/A
- SILO N/A
- EPS Growth
- BGLC N/A
- SILO N/A
- EPS
- BGLC N/A
- SILO N/A
- Revenue
- BGLC $9,259,858.00
- SILO $72,102.00
- Revenue This Year
- BGLC N/A
- SILO $1.86
- Revenue Next Year
- BGLC N/A
- SILO N/A
- P/E Ratio
- BGLC N/A
- SILO N/A
- Revenue Growth
- BGLC N/A
- SILO N/A
- 52 Week Low
- BGLC $0.21
- SILO $0.77
- 52 Week High
- BGLC $3.39
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- BGLC 59.27
- SILO 79.84
- Support Level
- BGLC $0.33
- SILO $1.62
- Resistance Level
- BGLC $0.41
- SILO $2.16
- Average True Range (ATR)
- BGLC 0.11
- SILO 0.31
- MACD
- BGLC 0.01
- SILO 0.10
- Stochastic Oscillator
- BGLC 23.68
- SILO 43.37
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.